Future challenges.
Treatment for patients with myeloma has changed unrecognisably over the last two decades and now includes a sequence of treatments including chemotherapy, biological targeted therapy with or without consideration for high-dose therapy (autologous and allogeneic stem cell transplantation for younger and fit patients). As patients can now expect a doubling of median survival and a 20-30% chance of surviving longer than 10 years, the focus of treatment is shifting to long-term quality of life. This article focuses on future challenges facing clinicians treating myeloma and how best we may optimize our resources.
Sirohi
B
B
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
Powles
R
R
D003131:Combined Modality Therapy / Q000639:trends; D003362:Cost-Benefit Analysis; D019468:Disease Management; D006801:Humans; D009101:Multiple Myeloma / Q000191:economics / Q000628:therapy*; D011788:Quality of Life